Beatrice Borelli

2.1k total citations
52 papers, 535 citations indexed

About

Beatrice Borelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Beatrice Borelli has authored 52 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Hepatology. Recurrent topics in Beatrice Borelli's work include Colorectal Cancer Treatments and Studies (42 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Gastric Cancer Management and Outcomes (12 papers). Beatrice Borelli is often cited by papers focused on Colorectal Cancer Treatments and Studies (42 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Gastric Cancer Management and Outcomes (12 papers). Beatrice Borelli collaborates with scholars based in Italy, United States and Japan. Beatrice Borelli's co-authors include Gianluca Masi, Carlotta Antoniotti, Chiara Cremolini, Filippo Pietrantonio, Sara Lonardi, Alfredo Falcone, Federica Marmorino, Lisa Salvatore, Fotios Loupakis and Veronica Conca and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Beatrice Borelli

45 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Beatrice Borelli Italy	12	435	160	147	105	82	52	535
Katia Dotti Italy	12	364 0.8×	114 0.7×	149 1.0×	99 0.9×	56 0.7×	28	514
Alberto F. Sobrero Italy	15	578 1.3×	151 0.9×	224 1.5×	130 1.2×	126 1.5×	66	697
C. Barone Italy	7	516 1.2×	165 1.0×	223 1.5×	179 1.7×	145 1.8×	19	682
Geoff Chong Australia	9	274 0.6×	111 0.7×	117 0.8×	105 1.0×	22 0.3×	25	414
Holger G. Hass Germany	13	384 0.9×	134 0.8×	208 1.4×	162 1.5×	86 1.0×	40	644
Janine M. Davies Canada	11	209 0.5×	89 0.6×	62 0.4×	85 0.8×	70 0.9×	42	377
Claire Greene United States	5	392 0.9×	158 1.0×	194 1.3×	114 1.1×	209 2.5×	8	511
Stephanie Yasmin Brule Canada	7	307 0.7×	137 0.9×	190 1.3×	77 0.7×	84 1.0×	18	397
Kota Ouchi Japan	12	251 0.6×	133 0.8×	110 0.7×	72 0.7×	163 2.0×	42	503
Yong Mun United States	11	313 0.7×	79 0.5×	115 0.8×	57 0.5×	32 0.4×	43	464

Countries citing papers authored by Beatrice Borelli

Since Specialization

Citations

This map shows the geographic impact of Beatrice Borelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatrice Borelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatrice Borelli more than expected).

Fields of papers citing papers by Beatrice Borelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatrice Borelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatrice Borelli. The network helps show where Beatrice Borelli may publish in the future.

Co-authorship network of co-authors of Beatrice Borelli

This figure shows the co-authorship network connecting the top 25 collaborators of Beatrice Borelli. A scholar is included among the top collaborators of Beatrice Borelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatrice Borelli. Beatrice Borelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Antoniotti, Carlotta, Federica Marmorino, Daniele Rossini, et al.. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 228. 115713–115713.

Conca, Veronica, Paola Vignali, Daniele Rossini, et al.. (2024). Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.. Journal of Clinical Oncology. 42(16_suppl). 3572–3572.

Conca, Veronica, Roberto Moretto, Carlotta Antoniotti, et al.. (2024). Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.. Journal of Clinical Oncology. 42(16_suppl). 3558–3558. 1 indexed citations

Boraschi, Piero, Roberto Moretto, Francescamaria Donati, et al.. (2023). Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging. Cancers. 15(8). 2200–2200. 3 indexed citations

Fanotto, V., Daniele Rossini, Mariaelena Casagrande, et al.. (2023). Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers. 15(22). 5451–5451. 1 indexed citations

Borelli, Beatrice, Marco Maria Germani, Bruno Manfredi, et al.. (2023). Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm. Critical Reviews in Oncology/Hematology. 186. 103985–103985. 7 indexed citations

Palmeri, Matteo, Andrea Peri, Niccolò Furbetta, et al.. (2022). Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. Updates in Surgery. 74(4). 1327–1335. 1 indexed citations

Germani, Marco Maria, Beatrice Borelli, Piero Boraschi, et al.. (2022). The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treatment Reviews. 106. 102382–102382. 12 indexed citations

Corti, Francesca, Sara Lonardi, Rossana Intini, et al.. (2021). The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer. 150. 155–167. 78 indexed citations

10.

Moretto, Roberto, Daniele Rossini, Iolanda Capone, et al.. (2021). Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer. 20(4). 314–317. 12 indexed citations

11.

Cremolini, Chiara, Daniele Rossini, Carlotta Antoniotti, et al.. (2021). LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO. Annals of Oncology. 32. S1294–S1295. 26 indexed citations

12.

Moretto, Roberto, Daniele Rossini, Veronica Conca, et al.. (2021). CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British Journal of Cancer. 125(6). 839–845. 10 indexed citations

13.

Miyamoto, Yuji, Marta Schirripa, Mitsukuni Suenaga, et al.. (2020). A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE. 15(9). e0239439–e0239439. 10 indexed citations

14.

Schirripa, Marta, Beatrice Borelli, Romina D’Aurizio, et al.. (2019). Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. The Pharmacogenomics Journal. 19(5). 455–464. 5 indexed citations

15.

Moretto, Roberto, Federica Morano, Elena Ongaro, et al.. (2019). Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer. 18(2). 116–124. 7 indexed citations

16.

Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2017). Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Annals of Oncology. 28. vi3–vi3. 2 indexed citations

17.

Antoniotti, Carlotta, Federica Marmorino, Marzia Pennati, et al.. (2017). Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. vi4–vi4. 3 indexed citations

18.

Santini, Daniele, Chiara Cremolini, Lisa Salvatore, et al.. (2017). Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO. Annals of Oncology. 28. vi9–vi9.

19.

Marmorino, Federica, Lisa Salvatore, C. Barbara, et al.. (2017). Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer. 116(3). 318–323. 33 indexed citations

20.

Schirripa, Marta, Fotios Loupakis, Chiara Cremolini, et al.. (2015). P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Annals of Oncology. 26. iv57–iv57. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact